Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus
Middle East respiratory syndrome coronavirus (MERS-CoV), first isolated in 2012, has emerged zoonotically among humans (van Boheemen et al.2012). Since then, MERS-CoV continues to be a public health concern, with a fatality rate of 35%. On-going MERS-CoV outbreaks highlight the urgent need for the development of interventional measures, including an effective vaccine against MERS-CoV infection. Currently, no licensed therapeutic or vaccine is available (Okba et al.2017).
MERS-CoV spike (S) protein mediates coronaviral penetration into host cells via initial interaction with the host cell surface receptor. Based on the major immunodominant region of S protein, vaccines against MERS-CoV infection have been developed using purified coronaviral S protein and DNA or viral vector-based vaccines expressing full-length MERS-CoV S protein or part of the S protein (Okba et al.2017). However, efforts are required to achieve optimal protective responses, such as a higher titer of...
This work was supported by the Megaproject for Infectious Disease Research of China (2016ZX10004001-003 and 2014ZX10004001-002 to W.T.), and the National Key Research and Development Program of China (2016YFD0500300 to W.T., 2016YFC1200901 to Y.D., and 2016YFC1200200 to B.H). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Compliance with Ethics Standards
Conflict of interest
The authors declare that they have no conflict of interest.
Animal and Human Rights Statement
Animal studies were conducted in strict accordance with the Guide for the Care and Use of Laboratory Animals of the People’s Republic of China. The study protocol was approved by the Committee on the Ethics of Animal Experiments of the Chinese Centre for Disease Control and Prevention.
- Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, Smith G (2011) Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine 29:6606–6613CrossRefGoogle Scholar
- van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, Fouchier RA (2012) Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 3:e00473–12Google Scholar